The ISHRS Achieves ACCME Accreditation with Commendation for Educational Activities

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

A user shared their progress after using a topical treatment combining 5% Minoxidil and 0.1% Finasteride for two months to address hair loss at the temples. They apply 5ml nightly without side effects and plan to switch to a different brand soon.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.